1. Scrip
  2. >>Business
  3. >>Financing

Glycomine Funds Phase IIb Rare Disease Trial With $115m Series C

Drug Developer Focused On Glycosylation Disorders

 
• By Mandy Jackson

Lead drug GLM101 will move into its first placebo-controlled trial based on positive results in adults and adolescents with PMM2-CDG in an open-label Phase IIa study.

Glycomine raises $115m in venture capital funding (Shutterstock)
Key Takeaways
  • Glycomine raised $115m in series C venture capital to run a Phase IIb clinical trial of GLM101 in phosphomannomutase-2 congenital disorder of glycosylation (PMM2-CDG).

Glycomine has spent more than a decade investigating the treatment of glycosylation disorders, starting with phosphomannomutase-2 congenital disorder of glycosylation...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

Finance Watch: BeOne Raises $885m In Imdelltra Royalty Sale

 
• By Mandy Jackson

BeOne could realize up to $950m under a deal with Royalty Pharma for its portion of sales from Amgen’s DLL3 inhibitor. Also, Novavax refinanced convertible debt, Kriya Therapeutics raised $313.3m in venture capital and Vaxxas garnered A$89.2m ($57.9m) in venture debt and cash.

Former Moderna Exec Launches Company Focused On mRNA Despite HHS Funding Cuts

 
• By David Wild

Emerging Company Profile: Axelyf raises $2.6m seed round for lipid nanoparticle delivery platform on heels of end to US federal support for mRNA vaccines.

Finance Watch: CSL Restructuring Brings 15% Workforce Reduction, Vaccines Group Spinout

 
• By Mandy Jackson

Restructuring Edition: CSL Group will spin out CSL Seqirus as a standalone vaccines business as the parent company slims down. Some struggling companies are turning to investing in cryptocurrencies to create shareholder value.

Finance Watch: Did Mid-Summer Usher In A Mega-Round Comeback?

 
• By Mandy Jackson

Private Company Edition: Hatteras Venture Partners now has more than $900m under management. Also, in recent $100m-plus VC rounds, Strand Therapeutics raised a $153m series A, ARTBIO revealed a $132m series B and Minghui Pharmaceutical secured a $131m pre-IPO round.

More from Rare Diseases

Rhythm Gets US Decision Date For Hypothalamic Obesity Treatment

 
• By Andrew McConaghie

Already approved in two rare obesity conditions, Rhythm’s Imcivree looks on course to gain acquired hypothalamic obesity approval and reach blockbuster status.

DMD Plans Remain Central For Regenxbio Despite Hunter Syndrome FDA Approval Delay

 
• By Manas Mishra

All eyes will be on Regenxbio's DMD data, expected next year, as the drug developer navigates a three-month delay to its FDA approval hopes for its Hunter syndrome gene therapy.

Egetis Eyes Swift US Submission For Emcitate

 
• By Kevin Grogan

The Sweden-based firm is set for talks with the FDA on the regulatory path for its MCT8 deficiency candidate.